MedTrace Logo

Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers

NCT02071615 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-04-17

No results posted yet for this study

Summary

In this study the investigators compare three stimulants to each other. The effects of these agents on cognitive performance (eg, attention and memory) and on the brain are being measured. The hypothesis is that stimulants will have a positive effect on cognitive performance.

Each study participant will receive once a placebo and once methylphenidate or modafinil or caffeine. Methylphenidate (also known as Ritalin ®) is a drug that is used in the treatment of attention deficit / hyperactivity disorder (ADHD) in children, adolescents and adults. Modafinil ( Vigil ®) is a drug used in the treatment of narcolepsy (sleeping sickness). In the study. These substances are given in the study only once and in the dosages in which is also used for the treatment of the above diseases. In the case of caffeine , the dosage corresponds to two cups of coffee.

Conditions

  • Healthy

Interventions

DRUG

Methylphenidate 20 mg tablet given once by mouth

3-arm, single-drug dosage comparison study

DRUG

modafinil 200mg tablet given once by mouth

3-arm, single-drug dosage comparison study

DRUG

caffein 200mg tablet given once by mouth

3-arm, single-drug dosage comparison study

DRUG

placebo

Sponsors & Collaborators

  • The Volkswagen Foundation

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Dimitris Repantis, MD · Department of Psychiatry and Psychotherapy, Charité - University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071615 on ClinicalTrials.gov